Edition:
United States

Teva Pharmaceutical Industries Ltd (TEVA.N)

TEVA.N on New York Stock Exchange

17.15USD
21 Sep 2017
Change (% chg)

$0.04 (+0.23%)
Prev Close
$17.11
Open
$17.12
Day's High
$17.33
Day's Low
$16.91
Volume
3,577,793
Avg. Vol
3,013,541
52-wk High
$51.50
52-wk Low
$15.22

Chart for

About

Teva Pharmaceutical Industries Limited is a pharmaceutical company. The Company is engaged in developing, producing and marketing generic medicines and a portfolio of specialty medicines. The Company operates through two segments: Generic medicines and Specialty medicines. The Company develops, manufactures and sells generic... (more)

Overall

Beta: 0.57
Market Cap(Mil.): $17,501.39
Shares Outstanding(Mil.): 1,014.36
Dividend: 0.09
Yield (%): 6.46

Financials

  Industry Sector
P/E (TTM): -- 31.87 16.33
EPS (TTM): -- -- --
ROI: -- 15.11 14.66
ROE: -- 16.37 13.99

LPC: Banks line up €430m loan for CVC’s Teva asset buy

LONDON Three banks have lined up €430m of leveraged loans to back private equity firm CVC Capital Partners’ acquisition of the remaining assets in Teva Pharmaceutical Industries’ women’s health business, banking sources said.

Sep 19 2017

UPDATE 1-LPC-Banks line up €430m loan for CVC’s Teva asset buy

LONDON, Sept 19 Three banks have lined up €430m of leveraged loans to back private equity firm CVC Capital Partners’ acquisition of the remaining assets in Teva Pharmaceutical Industries’ women’s health business, banking sources said.

Sep 19 2017

BRIEF-Teva and Nuvelution Pharma partner to accelerate development of Austedo tablets for use in Tourette Syndrome in the united states

* Teva and Nuvelution Pharma partner to accelerate development of austedo® (deutetrabenazine) tablets for use in tourette syndrome in the united states

Sep 19 2017

LPC-Banks line up €430m loan for CVC’s Teva asset buy

LONDON, Sept 19 Three banks have lined up around €430m of leveraged loans to back private equity firm CVC Capital Partners’ acquisition of the remaining assets in Teva Pharmaceutical Industries’ women’s health business, banking sources said.

Sep 19 2017

Fitch Affirms Jubilant Pharma at 'BB-'; Outlook Stable

(The following statement was released by the rating agency) SINGAPORE/MUMBAI, September 19 (Fitch) Fitch Ratings has affirmed Singapore-based Jubilant Pharma Limited's (JPL) Long-Term Foreign-Currency Issuer Default Rating (IDR) at 'BB-'. The Outlook is Stable. The agency has also affirmed JPL's senior unsecured rating and the rating on its USD300 million 4.875% senior unsecured notes due 2021 at 'BB'. JPL's ratings reflect moderate linkages with parent, Jubilant Life Sciences Limited (JLS), whi

Sep 19 2017

Teva Pharma to sell more women's health assets for $1.38 billion

TEL AVIV Teva Pharmaceutical Industries Ltd said on Monday it would sell the remaining assets in its specialty women's health business for $1.38 billion in two separate transactions.

Sep 18 2017

UPDATE 1-Teva Pharma to sell more women's health assets for $1.38 bln

TEL AVIV, Sept 18 Teva Pharmaceutical Industries Ltd said on Monday it would sell the remaining assets in its specialty women's health business for $1.38 billion in two separate transactions.

Sep 18 2017

Teva Pharma to sell some women's health assets for $1.38 bln

Sept 18 Teva Pharmaceutical Industries Ltd said on Monday it would sell some assets in its women's health business for $1.38 billion in two separate transactions.

Sep 18 2017

BRIEF-Teva announces sale of remaining assets in women’s health portfolio for $1.38 bln

* Teva announces sale of remaining assets in specialty global women’s health portfolio for $1.38 billion

Sep 18 2017

Teva to sell women's health assets to CVC Capital Partners: report

Teva Pharmaceutical Industries Ltd is close to a deal to sell its women's health assets outside the United States to private equity firm CVC Capital Partners, the Fly reported, citing Bloomberg.

Sep 13 2017

Competitors

  Price Chg
Novartis AG (NOVN.S) CHF82.95 --
Biogen Inc (BIIB.OQ) $315.03 -3.97

Earnings vs. Estimates